Will This Analyst Upgrade Help InterMune (ITMN) Stock Today? (Update)

Update (9:42 a.m.): Updated with Monday market open information.

NEW YORK (TheStreet) -- Leerink upgraded InterMune  (ITMN) to "outperform" from "market perform" and set a $41 price target. The firm noted the company posted better clinical data in two trials.

The stock was up 7.67% to $36.94 at 9:40 a.m. on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ITMN Chart

ITMN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000